2026 International Congress Archives - Page 117 of 208

Long-term exposure to fine particulate matter (PM2.5) is associated with earlier onset of Parkinson’s disease: a retrospective population-based cohort study

C. Santoro, M. Pesare, F. Catino, F. Castellana, N. Pilolli, A. Macerollo, G. Boero, R. Sardone (Taranto, Italy)
Long-Term Instability of GPi Gamma Oscillations in Parkinson’s Disease: A Case Study

Q. Yuan, J. Dang, T. Mehta, J. Cagle, C. de Hemptinne, J. Wong (Gainesville, USA)
Long-Term Open-Label Data on the GCase Modulator GT-02287 in People with Parkinson’s Disease

R. Pozzi, T. Ignoni, M. Bosetti, A. Barassi, M. Desciscio, A. Lehn, R. Schwartz, D. Thyagarajan, J. Taylor, J. Hannestad (Lugano, Switzerland)
Long-term outcomes and real-world implementation of adaptive deep brain stimulation in Parkinson’s disease

V. Witzig, J. Busch, J. Kaplan, J. Behnke, L. Drescher, J. Habets, A. Kühn (Berlin, Germany)
Long-term safety of deep brain stimulation (DBS): Real-world evidence

J. Joseph, Y. Pathak, C. Salazar, A. Benison (Austin, USA)
Long-term Safety of Opicapone in Parkinson’s Disease Patients with First Signs of Wearing-off

JJ. Ferreira, F. Stocchi, A. Antonini, O. Rascol, G. Ebersbach, J. Kulisevsky, N. Pavese, G. Hoglinger, D. Ramos, J-F. Rocha, HC. Brigas, J. Holenz, W. Poewe (Lisboa, Portugal)
Long-term therapeutic effects of repetitive transcranial magnetic stimulation combined with lidocaine injection (rTMS-LI) in dystonia

N. Muraser, R. Urushihara, H. Shimazu, S. Matsumoto, K. Satoh, K. Asanuma, R. Kaji (Nara city, Japan)
Long-term utilization of onabotulinumtoxinA for the treatment of cervical dystonia

R. Barbano, K. Dashtipour, D. Safarpour, M. Sadeghi, J. Zhao, K. Ifantides, A. Ukah, B. Jabbari (Rochester, USA)
Long‑term dose-effect patterns with incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in cervical dystonia: multicenter real‑world analysis

B. Waeschle, P. Albrecht, J. Lee, T. Kölsche, R. Jansen, P. Sobolewski, S. Sánchez Valiente, E. López Valdés, P. Mir, S. Jesús, E. Ojeda Lepe, E. Papuć, P. Sánchez Alonso, G. Salazar, G. Comes, H. Stark (Frankfurt, Germany)
Longitudinal Association Between Baseline CSF GFAP Levels and Clinical Progression in Parkinson’s Disease A PPMI Study

Z. Huseynli (Istanbul, Turkey)